These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 30142994)

  • 21. A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.
    Schlumberger M; Jarzab B; Cabanillas ME; Robinson B; Pacini F; Ball DW; McCaffrey J; Newbold K; Allison R; Martins RG; Licitra LF; Shah MH; Bodenner D; Elisei R; Burmeister L; Funahashi Y; Ren M; O'Brien JP; Sherman SI
    Clin Cancer Res; 2016 Jan; 22(1):44-53. PubMed ID: 26311725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of Multikinase Inhibitors for Patients With Refractory Thyroid Cancer: Systematic Review and Network Meta-Analysis.
    Jing R; Wu N; Wu Y; Zhang Q; Liang Q; Huang P; Yi S
    J Clin Endocrinol Metab; 2024 Sep; 109(10):2658-2672. PubMed ID: 38970485
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.
    Bible KC; Suman VJ; Molina JR; Smallridge RC; Maples WJ; Menefee ME; Rubin J; Karlin N; Sideras K; Morris JC; McIver B; Hay I; Fatourechi V; Burton JK; Webster KP; Bieber C; Traynor AM; Flynn PJ; Cher Goh B; Isham CR; Harris P; Erlichman C;
    J Clin Endocrinol Metab; 2014 May; 99(5):1687-93. PubMed ID: 24606083
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double-blind randomized phase 2 trial.
    Huang J; Xiao J; Fang W; Lu P; Fan Q; Shu Y; Feng J; Zhang S; Ba Y; Zhao Y; Liu Y; Bai C; Bai Y; Tang Y; Song Y; He J
    Cancer Med; 2021 Mar; 10(5):1681-1689. PubMed ID: 33586360
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hand-foot syndrome and survival in patients with advanced non-small-cell lung cancer receiving anlotinib: a subgroup analysis of data from the ALTER 0303 study.
    Nan X; Xie C; Zhu Q; Zhang J; Fu S; Han X; Zhang Q; Han B; Liu J
    Int J Clin Oncol; 2020 Aug; 25(8):1492-1498. PubMed ID: 32447474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer.
    Si X; Zhang L; Wang H; Zhang X; Wang M; Han B; Li K; Wang Q; Shi J; Wang Z; Cheng Y; He J; Shi Y; Chen W; Wang X; Luo Y; Nan K; Jin F; Li B; Chen Y; Zhou J; Wang D
    Lung Cancer; 2018 Aug; 122():32-37. PubMed ID: 30032842
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
    de Castroneves LA; Negrão MV; de Freitas RM; Papadia C; Lima JV; Fukushima JT; Simão EF; Kulcsar MA; Tavares MR; Jorge AA; de Castro G; Hoff PM; Hoff AO
    Thyroid; 2016 Mar; 26(3):414-9. PubMed ID: 26701095
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Long term follow-up results of anlotinib in the treatment of advanced renal cell carcinoma].
    Song Y; Yihebali C; Yang L; Cui CX; Zhang W; Sun YK; Du CX; Zhou AP; Wang JW
    Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):765-770. PubMed ID: 32988160
    [No Abstract]   [Full Text] [Related]  

  • 29. Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF).
    Leboulleux S; Kapiteijn E; Litière S; Schöffski P; Godbert Y; Rodien P; Jarzab B; Salvatore D; Zanetta S; Capdevila J; Bastholt L; De La Fouchardiere C; Lalami Y; Bardet S; Cornélis F; Dedecjus M; Links T; Sents W; Schlumberger M; Locati DL; Newbold K
    Front Endocrinol (Lausanne); 2024; 15():1403687. PubMed ID: 39015176
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Efficacy and safety of Anlotinib as a third-line chemotherapy for metastatic colorectal cancer].
    Li N; Huang Q; Zhang MJ; Chen ZD
    Zhonghua Yi Xue Za Zhi; 2019 Sep; 99(36):2844-2847. PubMed ID: 31550814
    [No Abstract]   [Full Text] [Related]  

  • 31. Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma.
    Chi Y; Fang Z; Hong X; Yao Y; Sun P; Wang G; Du F; Sun Y; Wu Q; Qu G; Wang S; Song J; Yu J; Lu Y; Zhu X; Niu X; He Z; Wang J; Yu H; Cai J
    Clin Cancer Res; 2018 Nov; 24(21):5233-5238. PubMed ID: 29895706
    [No Abstract]   [Full Text] [Related]  

  • 32. Vandetanib for the treatment of medullary thyroid carcinoma.
    Cooper MR; Yi SY; Alghamdi W; Shaheen DJ; Steinberg M
    Ann Pharmacother; 2014 Mar; 48(3):387-94. PubMed ID: 24259657
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lenvatinib: Role in thyroid cancer and other solid tumors.
    Cabanillas ME; Habra MA
    Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anlotinib for refractory advanced non-small-cell lung cancer: A systematic review and meta-analysis.
    Yu G; Shen Y; Xu X; Zhong F
    PLoS One; 2020; 15(11):e0242982. PubMed ID: 33253313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase II study (ALTER-0802 study).
    Sun Y; Zhou A; Zhang W; Jiang Z; Chen B; Zhao J; Li Z; Wang L; Bi X; Zhao H; Liu K
    Hepatol Int; 2021 Jun; 15(3):621-629. PubMed ID: 33826043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon alpha-2b and octreotide.
    Lupoli G; Cascone E; Arlotta F; Vitale G; Celentano L; Salvatore M; Lombardi G
    Cancer; 1996 Sep; 78(5):1114-8. PubMed ID: 8780551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma.
    Woyach JA; Kloos RT; Ringel MD; Arbogast D; Collamore M; Zwiebel JA; Grever M; Villalona-Calero M; Shah MH
    J Clin Endocrinol Metab; 2009 Jan; 94(1):164-70. PubMed ID: 18854394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of tumor cavitation in extensive-stage small-cell lung cancer patients treated with anlotinib.
    Chen D; Xu J; Zhao Y; Chu T; Zhong H; Han B; Zhong R
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):401-406. PubMed ID: 31691871
    [TBL] [Abstract][Full Text] [Related]  

  • 39. First Line Sorafenib Treatment for Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
    Kocsis J; Szekanecz É; Bassam A; Uhlyarik A; Pápai Z; Rubovszky G; Mezősi E; Rucz K; Garai I; Nagy E; Uray I; Horváth Z
    Exp Clin Endocrinol Diabetes; 2019 Apr; 127(4):240-246. PubMed ID: 29506310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma.
    de Groot JW; Zonnenberg BA; van Ufford-Mannesse PQ; de Vries MM; Links TP; Lips CJ; Voest EE
    J Clin Endocrinol Metab; 2007 Sep; 92(9):3466-9. PubMed ID: 17579194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.